Obstructive Airway Diseases. This item is unavailable.Obstructive Airway Diseases

Incidences of inflammatory airway diseases are on the rise across the world. Existing therapeutic options are ineffective, unsafe, and expensive, and severe cases are nonresponsive to conventional therapy. Therefore, it is imperative that research be undertaken to discover new treatment options. Obstructive Airway Diseases: Role of Lipid Mediators discusses clinically successful and potential lipid targets that can make a difference in treating some of the most intractable disease states.

Topics discussed include:

• Obstructive airway diseases, etiology, pathophysiology, and existing therapeutic options
• What constitutes a lipid and how it is broken down to generate biologically active mediators
• The role of enzymes in the process of lipid mediator synthesis
• The biology of arachidonic acid, platelet-activating factor, and lysophosphatidic acid and the role they play in airway inflammation
• Products of arachidonic acid metabolism such as leukotrienes, prostaglandins, epieicosatrienoic acid, and oxoeicosatetraenoic acid
• Proresolution lipid mediators in inflammatory airway disease conditions
• The role of sphingosine and ceramide in inflammatory airway disease
• Protein kinases activated by lipid mediators and those that trigger the generation of lipid messengers

The combined input of a panel of international authorities on lipid mediators makes this volume a valuable resource for all those involved in researching, teaching, and studying airway inflammation as well as those involved in drug discovery research.

Punit Srivastava maintains a blog with additional information about the book and his work.

Abhijit Ray has worked in human trials with molecules designed to treat airway inflammation associated with asthma and COPD and has published more than 60 articles in peer-reviewed journals. He has been the senior director and head of biology research at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. As a member of the drug discovery team, he manages a group of 60 scientists engaged in discovery research for drugs in the areas of infectious and inflammatory diseases.

Punit Srivastava has been a group leader of biology at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. He was a member of the drug discovery group of Ranbaxy Laboratories Ltd. from 2004 to June 2010 and has worked for more than six years in drug discovery research, which has resulted in one molecule entering human trial for COPD. He has published more than 15 articles in peer-reviewed journals and filed at least six patents. As a member of the drug discovery team at Daiichi Sankyo, he is leading projects in the area of inflammation.